SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)
-
Laura Ortega Morán [1] ; Francisco José Pelegrín Mateo [2] ; Rut Porta Balanyà [7] ; Jacobo Rogado Revuelta [3] ; Silverio Ros Martínez [8] ; José Pablo Berros Fombella [9] ; Elena María Brozos Vázquez [4] ; Natalia Luque Caro [10] ; José Muñoz Langa [5] ; Mercedes Salgado Fernández [6]
-
[1] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[2] Hospital de la Santa Creu i Sant Pau
Hospital de la Santa Creu i Sant Pau
Barcelona, España
-
[3] Hospital Infanta Leonor
Hospital Infanta Leonor
Madrid, España
-
[4] Complexo Hospitalario Universitario da Coruña
Complexo Hospitalario Universitario da Coruña
A Coruña, España
-
[5] Hospital Arnau de Vilanova
Hospital Arnau de Vilanova
Valencia, España
-
[6] Complexo Hospitalario Universitario de Ourense
Complexo Hospitalario Universitario de Ourense
Ourense, España
-
[7] Hospital Universitari Dr. Josep Trueta, ICO Girona, Girona, Spain
-
[8] Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
-
[9] Hospital Universitario San Agustín, Avilés, Asturias, Spain
-
[10] Hospital Universitario Jaén, Jaén, Spain
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2877-2901
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.
